

Healthy Volunteers

## A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants

**Trial Status**  
Completed

**Trial Runs In**  
1 Country

**Trial Identifier**  
NCT06835465 GP45718

*The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.*

### Official Title:

A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Subjects

### Trial Summary:

This is a phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of rifampin on the pharmacokinetics (PK) and safety of divarasib in healthy participants.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

**NCT06835465 GP45718**  
Trial Identifiers

### Eligibility Criteria:

**Gender**  
All

**Age**  
#18 Years & # 60 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

### Inclusion Criteria:

- Males or females of non-childbearing potential
- Within body mass index (BMI) range of 18.0 to 32.0 kg/m<sup>2</sup>, inclusive

### Exclusion Criteria:

# ForPatients

*by Roche*

- Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
- Poor peripheral venous access